JAB Averse is now happy!
ELI Lilly, a pharmaceutical manufacturer, announced that this week’s encouraging clinical trial for a new pill promises to be convenient and stabbing to treat diabetes and obesity.
Company Stocks increased 15%. As a result of a test that showed a pill called Orforglipron, patients with type 2 diabetes helped weight loss at a level similar to major drugs such as Ozempic.
“This is potentially great development for patients who want an option without needles for weight and glucose management.” Lily said in a statement.
Experimental pills belong to the same kind of drugs as Ozempic and Wegovy.
Known as an GLP -1 receptor agent, the drug imitates a hormone called glucagon -like peptide -1 that controls appetite, insulin secretion and blood sugar.
It was first developed to treat type 2 diabetes, but GLP-1 drugs have soared due to significant weight loss capacity. The demand for these therapies has soared in recent years.
However, these drugs should be taken as a weekly injection per share that restricts access, use and appeals, and the development of oral alternatives is the top priority of the pharmaceutical.
If approved, ORFORGLIPRON can reconstruct the landscape by providing a more convenient and cost -friendly pill -based approach with a similar effect.
How long should we wait until the customer is released to the market?
Representatives of Lilly said the company plans to approve FDA to sell drugs for weight loss this year and sentenced diabetes in 2026.
The FDA’s review may take several months, but analysts speculate that if you make a plan, you can use it in the United States by the second half of next year.
Lilly is strengthening its pill supply to fight the shortage.
The company recently unveiled an inventory of nearly $ 550 million inventory, “mainly related to Orflipron.”
What is the cost of new weight loss pill?
The company will not set the drug price before being approved.
sugar New York TimesAnalysts suspect that sticker prices (starting prices of insurance negotiations) are likely to be less than $ 1,000 a month and will be slightly lower than the company’s injection ($ 1,086) and WEGOVY ($ 1,349).
What I found in clinical trials
LILLY’s clinical trials have been followed by more than 500 people with type 2 diabetes taking Orforglipron or placebo for nearly 10 months.
Participants who participated in the highest dose of the pill lost almost 8%of the average of 16 pounds or weight. This weight loss level is consistent with the amount spilled for the same period using Ozempic.
Orforglipron also reduced the patient’s blood sugar levels on average by 1.3%.
What are the side effects?
In terms of side effects, LILLY reported that the most common dissatisfaction in the ORFORGLIPRON clinical trial was that it was aftereffects, indigestion, constipation, nausea and vomiting that matched the use of the injectable GLP-1 drugs.
Lilly said that the participants of the Orforglipron test did not show signs of liver damage.
Other pills under development
Lily to create an injectable drug Zepbound To treat obesity As and difficult To treat diabetes, it is one of the many manufacturers who raced to bring a treatment without needles. To the market.
Some other companies are making their own GLP-1 pills. But Orforglipron is more developed and theoretically ahead of FDA approval.
This week’s pharmaceutical company gave up the development of GLP-1 pills after the test participants experienced “potential drug-induced damage”.
Lily continues to study other large or poggle lifron, and is studying the effects of drugs on patients with diabetes, obesity and obesity, such as sleep apnea and heart disease. Obestiy patients are expected to be expected at the end of this year and have test results for patients with type 2 diabetes, which are expected in early 2026.
